Andreessen Horowitz's new fund will pursue opportunities in the life sciences and healthcare technology, along with some that go beyond human health.simply click here to claim your deal and get access to all exclusive Business Insider PRIME content.
At $750 million, the third fund is bigger than the first two combined. All of the funds are focused on companies at the intersection of technology, healthcare and biopharma. The Silicon Valley venture capital firm is best known for its technology investments, including early bets on Facebook, Instagram, Lyft, and Slack, among others.
The initial duo of general partners, Jorge Conde and Vijay Pande, spoke with Business Insider ahead of the third fund's announcement. Here's what they had to say about their investing priorities and what's driving their excitement about biotech.As the funds have grown in size, so have their ambitions. was expecting the convergence of the technology, biopharma and healthcare industries.
The third fund will target life sciences and healthcare technology companies like the first two, Conde said, but it will also consider making investments in companies using biology beyond the healthcare industry. While future generations of these technologies will continue to improve, the fund is also open to exploring new therapeutic platforms and identifying when they can jump from concept to business.
United States United States Latest News, United States United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »